The Massachusetts-based biotech plans to use the funds to push its candidates into mid-stage clinical trials in a space ...

The effect of cystic fibrosis on many organs and the frequent lung infections means that it is mostly diagnosed in childhood. Somehow, for Verônica Stasiak Bednarczuk, that diagnosis did not arrive ...

Tauranga boy Riaan Hamilton has cystic fibrosis - the 3-year-old often gets sick, has been hospitalised several times, and is ...

Vertex Pharma has claimed an ultra-fast approval in the US for Trikafta, its three-drug combination that provides a treatment option for up to 90% of patients with the genetic disease cystic fibrosis.

Vertex sees 2025 revenue of $11.75 billion to $12.0 billion, the midpoint of which is above analysts' average expectation of ...

Vertex Pharmaceuticals Incorporated VRTX reported adjusted earnings of $3.98 per share for the fourth quarter of 2024, ...

Aucklander Ben Prince-Saxon is pushing the boundaries of what's possible living with cystic fibrosis.

The cystic fibrosis treatment leader exceeded revenue expectations, but missed slightly on earnings per share.

With a rise in Trikafta demand, the investors have assigned a higher valuation multiple for VRTX stock. The increase in VRTX ...

The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...

The fourth-quarter earnings season for the biotech sector is in full swing this week. A few bigwigs have already reported ...

Vertex Pharmaceuticals dominates the market for cystic fibrosis drugs, but Sionna Therapeutics contends the pharma company’s products still have efficacy and safety limitations. Sionna has ...